Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-10-09
2000-05-23
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514317, 514651, A61K 31505, A61K 31445, A61K 31135
Patent
active
060666439
ABSTRACT:
The present invention provides a method for producing a potentiating effect on a therapeutic action of an agent which is selected from a serotonin re-uptake inhibitor, a norepinephrine re-uptake inhibitors, both a serotonin and norepinephrine re-uptake inhibitor, and an atypical antidepressant in a warm blooded mammal, which comprises administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4952410 (1990-08-01), Armah et al.
patent: 5552429 (1996-09-01), Wong et al.
patent: 5712283 (1998-01-01), Kaan et al.
Michael Bourin, et.al., "Clonidine As a Sensitizing Agent in the Forced Swimming Test for Revealing Antidepressant Activity", J Psychiatr Neurosci, vol. 16, No. 4, pp. 199-203 (1991).
John E. Piletz and Angelos Halaris, "Involvement of I.sub.1 -Imidazoline Receptors in Mood Disorders", Annals New York Academy of Science, vol. 763, pp. 510-519, (1995).
M. Hascoet, et.al., "Behavioral models in mice. Implication of the alpha noradrenergic system", Prog. Neuropsychopharmacol Biol Psychiatry, 15 (6), pp. 825-840 (1991) (Abstract).
M. Hascoet, et.al., "Additive effect of lithium and clonidine with 5-HT1A agonists in the forced swimming test", Prog Neuropsychopharmacol Biol Psychiatry, 18 (2), pp. 381-396 (1994) (Abstract).
J.P. Redrobe and M. Bourin, "Effects of pretreatment with clonidine, lithium and quinine on the activites of antidepressant drugs in the mouse tail suspension test", Fundam Clin Pharmacol, 11 (5), pp. 381-386 (1997) (Abstract).
T.F.Meert and M. De Kock, "Potentiation of the analgesic properties of fentanyl-like opioids with alpha 2-adrenoceptor agonists in rats"., Anesthesiology, 81 (3), pp. 677-688, September (1994) (Abstract).
V. Jevtovic-Todorovic, et.al., "Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects", Brain Res, 781 (1-2), pp. 202-211, (1998) (Abstract).
Y.W. Lee and T.L. Yaksh, "Analysis of drug interaction between intrathecal clonidine and MK-801 in peripheral neuropathic pain rat model", Anesthesiology, 82 (3), pp. 741-748, March (1995) (Abstsract).
T.F. Mert and M. De Kock, "Interactions between the lipophilic opioid sufentanil and clonidine in rats after spinal application", Acta Anaesthesiol Scand, 39 (4), pp. 527-534, May (1995) (Abstract)
S. Hedges, et.al., "Clonidine does not potentiate the antipsychotic effects of neuroleptics in chronically ill patients", Ann Clin Psychiatry, 10 (1), pp. 3-7, March (1998) (Abstract).
N.J. Carrey, et.al., "Pharmacological treatment of psychiatric disorder in children and adolescents: focus on guidelines for the primary care practitioner", Drugs, 51 (5), pp. 750-759, May (1996) (Abstract).
Demeter John C.
Eli Lilly and Company
Henley III Raymond
LandOfFree
Potentiation of pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Potentiation of pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potentiation of pharmaceuticals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1837295